Table 4 Results of changing drug and testing protocol for anti-malarial drug distribution compared to a strategy of three rounds mass test and treat with artemether-lumefantrine at 72 % coverage per round of all ages of the population with 60 days between rounds
% Change in median parasite prevalence (IQR) compared to baseline strategy, by pre-intervention mean parasite prevalence | |||||||
|---|---|---|---|---|---|---|---|
% | Baseline intervention strategy | MTAT with DHAP | MTAT with DHAP + ivermectin | MDA with DHAP | MDA with DHAP + ivermectin | MDA with DHAP + SLD primaquine | MDA with DHAP + ivermectin + SLD primaquine |
<10 | MTAT with AL, 72 % coverage, 60 day frequency between rounds, targeting all ages | 0.56 (−25.5, 52.4) | 4.5 (−28.0, 50.10 | −7.6 (−32.2, 25.5) | −3.6 (−30.5, 33.9) | −17.1 (−35.0, 33.6) | −12.3 (−32.8, 32.2) |
10–24 | −7.2 (−27.0, 15.3) | −8.8 (−28.6, 16.3) | −33.0 (−56.0, −16.0) | −33.5 (−48.1, −9.5) | −35.7 (−56.7, −10.8) | −39.0 (−53.5, −10.8) | |
>24 | −0.2 (−11.9, 11.4) | −1.1 (−13.6, 9.7) | −44.1 (−53.6, −21.9) | −43.6 (−56.1, −33.7) | −36.4 (−55.4, −27.2) | −40.4 (−55.1, −28.4) | |